Medicare Enrolled
Dr. Jeffrey Wolf, M.D.
Pulmonary Disease · Great Neck, NY
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Wolf from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Wolf?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Wolf
Dr. Jeffrey Wolf is a pulmonary disease specialist in Great Neck, NY, with 20 years of NPI registration. Based on federal Medicare data, Dr. Wolf performed 2,767 Medicare services across 1,963 unique beneficiaries.
Between the years covered by Open Payments, Dr. Wolf received a total of $792,259 from 59 pharmaceutical and/or device companies across 2111 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in pulmonary disease. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Wolf is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 14% volume in NY
$792,259 industry payments
Medicare Practice Summary
Medicare Utilization ↗2,767
Medicare services
Top 14% in NY for pulmonary disease
1,963
Unique beneficiaries
$103
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~138 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
786 | $114 | $442 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
318 | $111 | $406 |
| Critical care, first 30-74 min Emergency medical care for a critically ill or injured patient lasting between 30 and 74 minutes. This service involves direct patient care and medical decision making to stabilize the patient. |
271 | $201 | $735 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
246 | $73 | $270 |
| Expiratory airflow and volume test A test that measures the amount of air you can exhale and the speed at which you can breathe it out. It evaluates lung function by assessing expiratory airflow and volume. |
219 | $25 | $96 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
168 | $162 | $591 |
| Lung volume test using sensors A test that measures the amount of air in the lungs using sensors. |
165 | $53 | $194 |
| Pulmonary gas exchange test A test to examine how well the lungs exchange gases. |
165 | $54 | $203 |
| Spirometry test before and after medication A test that measures the amount of air you can exhale and the speed of your breathing before and after taking a medication. |
87 | $38 | $138 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
80 | $156 | $579 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
57 | $73 | $313 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
54 | $162 | $595 |
| Chest X-ray, 2 views An X-ray imaging test of the chest that captures two different angles to visualize the lungs, heart, and chest wall. |
51 | $32 | $116 |
| Flu vaccine, quadrivalent A flu shot containing four strains of the influenza virus to help prevent seasonal influenza infection. |
33 | $76 | $200 |
| Flu vaccine administration This procedure involves the administration of the influenza virus vaccine. It covers the process of delivering the vaccine to the patient. |
33 | $36 | $85 |
| Chest X-ray, 1 view An X-ray image of the chest taken from a single angle. This imaging test is used to visualize the structures within the chest cavity. |
19 | $26 | $94 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
15 | $104 | $394 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$792,259
Total received (2018-2024)
Avg $113,180/year across 7 years
Top 0% in NY for pulmonary disease
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
59
Companies
2,111
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$742,341 (93.7%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$31,502 (4.0%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$18,415 (2.3%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$197,787
2023
$177,789
2022
$69,792
2021
$70,705
2020
$38,421
2019
$144,991
2018
$92,773
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
GENZYME CORPORATION
$52,157
GlaxoSmithKline, LLC.
$40,941
Regeneron Healthcare Solutions, Inc.
$35,491
AstraZeneca Pharmaceuticals LP
$33,393
Mylan Specialty L.P.
$25,577
Boehringer Ingelheim Pharmaceuticals, Inc.
$9,170
Grifols USA, LLC
$246
Electromed, Inc.
$222
Novartis Pharmaceuticals Corporation
$134
Baxter Healthcare
$111
Actelion Pharmaceuticals US, Inc.
$62
Philips North America LLC
$58
Vifor Pharma, Inc.
$55
Insmed, Inc.
$51
PFIZER INC.
$39
INOGEN, INC.
$23
ANI Pharmaceuticals, Inc.
$20
Shionogi Inc
$18
United Therapeutics Corporation
$18
Top 3 companies account for 65.0% of 2024 payments
All-time payments by company (2018-2024) ›
GlaxoSmithKline, LLC.
$140,084
AstraZeneca Pharmaceuticals LP
$127,546
Genentech USA, Inc.
$116,058
GENZYME CORPORATION
$100,805
Boehringer Ingelheim Pharmaceuticals, Inc.
$99,022
Regeneron Healthcare Solutions, Inc.
$81,188
Mylan Specialty L.P.
$76,545
Insmed, Inc.
$20,719
Sunovion Pharmaceuticals Inc.
$9,095
Advanced Respiratory, Inc
$4,176
ADVANCED RESPIRATORY, INC
$3,995
Ethicon Inc.
$3,349
Philips Electronics North America Corporation
$1,922
Grifols USA, LLC
$1,280
Novartis Pharmaceuticals Corporation
$1,038
Actelion Pharmaceuticals US, Inc.
$911
Mallinckrodt Hospital Products Inc.
$635
Electromed, Inc.
$605
Baxter Healthcare
$487
Amgen Inc.
$220
Mallinckrodt Enterprises LLC
$201
PFIZER INC.
$154
Covidien LP
$154
Teva Pharmaceuticals USA, Inc.
$151
Inogen, Inc.
$148
Takeda Pharmaceuticals U.S.A., Inc.
$145
Inspire Medical Systems, Inc.
$141
Medical Device Business Services, Inc.
$127
Medtronic, Inc.
$127
Pulmonx Corporation
$125
Harmony Biosciences LLC
$103
SANOFI-AVENTIS U.S. LLC
$87
Janssen Pharmaceuticals, Inc
$83
Shire North American Group Inc
$60
Philips North America LLC
$58
Vifor Pharma, Inc.
$55
Regeneron Pharmaceuticals, Inc.
$53
United Therapeutics Corporation
$50
Chiesi USA, Inc.
$48
JAZZ PHARMACEUTICALS INC.
$44
Genentech, Inc.
$40
Circassia Pharmaceuticals Inc
$38
Gilead Sciences, Inc.
$34
Paratek Pharmaceuticals, Inc.
$34
Cumberland Pharmaceuticals, Inc.
$32
Galvanize Therapeutics, Inc
$29
INOGEN, INC.
$23
OptiNose US, Inc.
$23
BOSTON SCIENTIFIC CORPORATION
$22
Mallinckrodt LLC
$21
Merck Sharp & Dohme LLC
$21
Resmed Corp
$21
Alexion Pharmaceuticals, Inc.
$20
Phadia US Inc.
$20
ANI Pharmaceuticals, Inc.
$20
Boston Scientific Corporation
$20
Shionogi Inc
$18
Veran Medical Technologies, Inc.
$15
Merck Sharp & Dohme Corporation
$14
Top 3 companies account for 48.4% of all-time payments
Associated products mentioned in payments ›
(8874) inCourage · (8876) Vest Therapy Und · (AK6) Vest Therapy · ACQUIRE · ACTHAR · AIRSENSE · AIRSUPRA · ALIYA SYSTEM · ANORO · ANORO ELLIPTA · APTIOM · ARALAST · AREXVY · ASMANEX · AirDuo Digihaler · Arikayce · BEVESPI AEROSPHERE · BREO · BREZTRI · BREZTRI AEROSPHERE · CALDOLOR · CINQAIR · CLEVIPREX · COMIRNATY · Caldolor · CoreDx · DUPIXENT · Dymista · Edge Navigation · Esbriet · FARXIGA · FASENRA · Fetroja · GLASSIA · Hillrom - Life 2000 Ventilation System · Hillrom - Vest System Model 105 Home Care · Hillrom - VisiVest Airway Clearance System · INOGEN AT HOME STATIONARY CONCENTRATOR · INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH · ImmunoCAP · Inspire Upper Airway Stimulation System · LONHALA MAGNAIR · Life 2000 Ventilation System · Monarch Platform · NO PRODUCT DISCUSSED · NUCALA · NUZYRA · OFEV · OPSUMIT · OPSUMIT MACITENTAN · PREVNAR - 13 · PREVNAR 13 · PREVNAR 20 · PURIFIED CORTROPHIN GEL · Prolastin-C · Prolastin-C Liquid · Pulmonx Endobronchial Valve EBV · QVAR · Respiratoriy Care Undiv · SEEBRI · SMARTVEST · SPIRIVA · SPIRIVA RESPIMAT · SRC Und · STIOLTO · STIOLTO RESPIMAT · SYMBICORT · Spin · TEZSPIRE · TRELEGY ELLIPTA · TUDORZA PRESSAIR · TYVASO · The MetaNeb System · The Monarch Airway Clearance System · The Vest System Model 105 Home Care · The VisiVest Airway Clearance System · Trilogy 100 · ULTOMIRIS · UPTRAVI · UTIBRON · Utibron · VT Und · WAKIX · Wakix · Wellcentive Undiv · XARELTO · XOLAIR · XYREM · Xhance · Xolair · YUPELRI · Yupelri · Zemaira · inCourage · superDimension
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (94%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in pulmonary disease and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 0% for pulmonary disease in NY.
Geographic Context
Pulmonary diseases within 10 mi
628
Per 100K population
45.2
County median income
$143,408
Nearest hospital
NORTH SHORE UNIVERSITY HOSPITAL
2.4 mi
2.4 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Wolf is a clinical cardiology specialist, with above-average Medicare volume (top 14% in NY), with speaking/promotional industry engagement in the top 0% of NY peers, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Wolf experienced with office visit, established patient (30-39 min)?
Based on Medicare claims data, Dr. Wolf performed 786 office visit, established patient (30-39 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Wolf receive payments from pharmaceutical companies?
Yes. Dr. Wolf received a total of $792,259 from 59 companies across 2,111 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Wolf's costs compare to other pulmonary diseases in Great Neck?
Dr. Wolf's average Medicare payment per service is $103. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Wolf) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Pulmonary Disease
Common procedures, typical costs, and what industry payments mean in pulmonary disease.
Same specialty & city
Pulmonary Diseases in Great Neck
Browse pulmonary diseases in Great Neck ranked by procedure volume and transparency data.
Highest volume
Top Pulmonary Diseases in NY
Pulmonary diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Pulmonary Diseases in NY
Which NY pulmonary diseases receive the most from drug and device companies.
By company
GlaxoSmithKline, LLC. Payments to Doctors
See all physicians who received payments from GlaxoSmithKline, LLC.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Genentech USA, Inc. Payments to Doctors
See all physicians who received payments from Genentech USA, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology